Printer Friendly

WATSON PHARMACEUTICALS RECEIVES FDA APPROVAL FOR TWO OFF-PATENT DRUGS

 CORONA, Calif., Sept. 27 /PRNewswire/ -- Watson Pharmaceuticals Inc. (NASDAQ: WATS) today announced that its wholly owned subsidiary, Watson Laboratories Inc., has received approval from the Food and Drug Administration (FDA) for off-patent forms of Estropipate tablet and Triamterene 37.5 milligram/Hydochlorothiazide 25 milligram tablet.
 According to Allen Chao, president and chief executive officer, the Estropipate tablet approval was for four dosage strengths; 0.75 milligram, 1.5 milligram, 3 milligram, and 6 milligram. The Watson off- patent product will compete with Abbott Laboratories' Ogen(R). Ogen is used as a hormone replacement therapy in post-menopausal treatment. In addition, the drug is one of a limited number of products that has an indication as a prophylaxis for osteoporosis. Total annual market value is estimated to be $60 million and Watson is the first off-patent pharmaceutical manufacturer to receive FDA approval for all dosage strengths of Estropipate tablet.
 Triamterene 37.5 milligram/Hydrochlorothiazide 25 milligram tablet will compete against Lederle's Maxide 25(R) and addresses an annual market estimated to be $30 million. The product is used as a diuretic, anti-hypertensive drug.
 "These two approvals bring our total number of approved products during 1993 to five," stated Chao. "We are particularly excited about the near- and long-term potential for Estropipate due to its growing sales in recent years. While the market for Triamterene 37.5 milligram/Hydrochlorothiazide 25 milligram is somewhat smaller, we believe that this product will contribute to 1994 financial results."
 Watson Pharmaceuticals manufactures and distributes off-patent pharmaceuticals and is developing advanced drug delivery systems designed to enhance the therapeutic benefits of pharmaceutical compounds.
 -0- 9/27/93
 /CONTACT: Doug Sherk or Stu Brunet, 415-296-7383; or Lisa Carlton or Miriam Adler, 212-850-5600, all of Morgen-Walke Associates for Watson Pharmaceuticals/
 (WATS)


CO: Watson Pharmaceuticals Inc. ST: California IN: MTC SU:

PK-LH -- SF002 -- 5737 09/27/93 06:30 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 27, 1993
Words:309
Previous Article:VALENCE TECHNOLOGY SIGNS $40 MILLION AGREEMENT TO OPEN NORTHERN IRELAND MANUFACTURING PLANT; FIRST COMMERCIAL BATTERIES IN 1994
Next Article:ENTERGY ENTERPRISES AND FIRST PACIFIC NETWORKS ADD SOUTHERN COMPANY TO POWERVIEW(TM) DEVELOPMENT EFFORTS
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters